<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826916</url>
  </required_header>
  <id_info>
    <org_study_id>DX-88/5</org_study_id>
    <secondary_id>EDEMA2</secondary_id>
    <nct_id>NCT01826916</nct_id>
  </id_info>
  <brief_title>EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema</brief_title>
  <official_title>EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and
      efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients
      with Hereditary Angioedema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of attacks treated with successful outcome</measure>
    <time_frame>24 hours</time_frame>
    <description>successful outcome is defined as attack resolution begun within 4 hrs after treatment and maintained for 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of attacks with a partial response</measure>
    <time_frame>24 hours</time_frame>
    <description>partial response is defined as an initial response to dosing followed by a relapse within 4 to 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who respond to a 2nd dose of ecallantide after an initial, partial response</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution onset of each acute attack, as determined by patient report</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>5mg/m2 DX-88 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/m2 DX-88 (ecallantide)administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg/m2 DX-88 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/m2 DX-88(ecallantide)administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg/m2 DX-88 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/m2 DX-88 (ecallantide) administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg DX-88 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg DX-88(ecallantide)administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DX-88 (ecallantide)</intervention_name>
    <description>solution for injection 10 mg/mL</description>
    <arm_group_label>5mg/m2 DX-88 IV</arm_group_label>
    <arm_group_label>10mg/m2 DX-88 IV</arm_group_label>
    <arm_group_label>20mg/m2 DX-88 IV</arm_group_label>
    <arm_group_label>30 mg DX-88 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 years of age or older

          -  Documented diagnosis of HAE (Type I or II)

          -  Patient reported to a study site no later than 4 hours following patient recognition
             of the onset of the attack

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Patients with a serious intercurrent illness or serious active infection

          -  Patient with serum creatinine greater than 110% the upper limit of normal or liver
             transaminases 2 times the upper limit of normal

          -  Receipt of an investigational drug or device, within 30 days prior to study treatment

          -  Pregnancy or breastfeeding

          -  Diagnosis of acquired angioedema (AAE)

          -  Patients who had not completed their Day-7 follow-up procedures for a previously
             treated attack
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <name_title>Bill Pullman, MD, PhD, Executive Vice President, Chief Development Officer</name_title>
    <organization>Dyax Corp.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

